Competitors Surge While Handok’s 70th Anniversary Marks a Setback
Handok CEO Kim Young-jin, Baek Jin-ki [photo=Handok] “We will show a dynamic development on the 70th anniversary of our founding. 2024 will be the year of a turnaround in growth.”…
Epilepsy Drug ‘Cenobamate’ Nears Korea Launch…Dong-A ST applies for approval
XCOPRI. [photo=SK Biopharmaceuticals] The domestic introduction of SK Biopharmaceuticals’ epilepsy drug ‘Cenobamate’ (marketed as ‘Xcopri’ in the U.S.) is underway. Cenobamate, first launched in the U.S., has rapidly expanded its…
Livalozet Faces Fierce Generic Challenge… Will JW Pharmaceutical Stand Firm?
JW Pharmaceutical’s hyperlipidemia combination product, Livalozet which combines pitavastatin and ezetimibe and accounts for 10% of its total sales is expected to face fierce competition from generic drugs this year.…
SK Biopharm Strengthens R&D with Former GSK Experts at U.S. Subsidiary
SK Biopharm is strengthening its research and development capabilities by securing top-tier talent. The company announced on the 17th that its U.S.-based research-focused subsidiary, SK Life Science Labs, has recruited…
LAZCLUZE·RYBREVANT Combo: A Game Changer for EGFR Mutant Lung Cancer
The combination therapy of LAZCLUZE(Lazertinib) and RYBREVANT(Amivantamab) has demonstrated superior effectiveness compared to existing monotherapies in treating atypical EGFR mutation non-small cell lung cancer (NSCLC). A study led by Professor…
Celltrion’s Vegzelma overtakes Roche’s Avastin in Europe
Celltrion’s metastatic colorectal and breast cancer treatment Vegzelma (bevacizumab) has surpassed Roche’s original drug Avastin, becoming the most prescribed bevacizumab product in Europe. On the 5th, Celltrion announced that Vegzelma…
'JaQBo' Makes Entry into Major Hospitals, Targets GERD Market
'JaQBo(zastaprazan citrate)', South Korea's 37th domestically developed new drug, is gaining traction in major hospitals across the country. Developed by Onconic Therapeutics, a subsidiary of Jeil Pharmaceutical, the potassium-competitive acid…
Daewoong Pharmaceutical Publishes Updated Insights on UDCA
Daewoong Pharmaceutical has unveiled the third edition of its comprehensive guide, 'Updated Insights on Urusa' which highlights recent global research on ursodeoxycholic acid (UDCA), the main component of its flagship…
One Year After Acquiring LigaChem: Orion’s 'Golden Goose'?
On January 15, 2023, Orion announced the acquisition of a 25.73% stake in LigaChem Biosciences for KRW 584.8 billion (approximately USD 470 million). Orion participated in LigaChem's third-party share issuance…
Samsung Biologics Lands Record $1.41 Billion CMO Deal
Samsung Biologics has started the year with a bang, signing its largest contract to date. On January 14, the company announced via regulatory filing that it had secured a massive…